IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$37.56 USD
-0.55 (-1.44%)
Updated Jun 17, 2024 04:00 PM ET
After-Market: $37.51 -0.05 (-0.13%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
IDEAYA Biosciences, Inc. (IDYA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$54.45 | $65.00 | $46.00 | 42.88% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for IDEAYA Biosciences, Inc. comes to $54.45. The forecasts range from a low of $46.00 to a high of $65.00. The average price target represents an increase of 42.88% from the last closing price of $38.11.
Analyst Price Targets (11)
Broker Rating
IDEAYA Biosciences, Inc. currently has an average brokerage recommendation (ABR) of 1.09 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.09 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, 10 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 90.91% and 9.09% of all recommendations. A month ago, Strong Buy made up 90.91%, while Buy represented 9.09%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 10 | 11 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.09 | 1.09 | 1.09 | 1.09 | 1.08 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/23/2024 | Capital One Securities | Timothy Chiang | Strong Buy | Strong Buy |
5/7/2024 | Wedbush Securities | Robert Driscoll | Strong Buy | Strong Buy |
3/8/2024 | BTIG | Justin R Zelin | Not Available | Strong Buy |
2/23/2024 | SVB Securities | Andrew Berens | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.09 |
ABR (Last week) | 1.09 |
# of Recs in ABR | 11 |
Average Target Price | $54.45 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.56 |